Get started
Author

Clemens Gießen-Jung

Observed names: C Gießen-Jung, C. Giessen-Jung, C. Gießen-Jung, C., Giessen-Jung, CLEMENS GIESSEN-JUNG, Clemens Giessen-Jung, Giessen-Jung, C., Giessen-Jung, Clemens
Observed institutions: German Cancer Research Center, LMU Klinikum, Humboldt-Universität zu Berlin, München Klinik, Klinikum Ingolstadt, Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases, Deutsches Konsortium für Translationale Krebsforschung, Charité – Universitätsmedizin Berlin, Ludwig-Maximilians-Universität München
ORCID: 0000-0003-0537-1727
Observed ORCID: 0000-0003-0537-1727
OpenAlex ID: A5006477894
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
2016 · Sebastian Stintzing, Dominik P Modest, et al. · The Lancet Oncology · 420
Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group
2016 · D.P. Modest, I. Ricard, et al. · Annals of Oncology · 370
PDF
Early tumour shrinkage (ETS) and depth of response (DpR) in the treatment of patients with metastatic colorectal cancer (mCRC)
2015 · Volker Heinemann, Sebastian Stintzing, et al. · European Journal of Cancer · 188
COVID-19 in cancer patients: clinical characteristics and outcome—an analysis of the LEOSS registry
2020 · on behalf of the LEOSS Study Group, Maria Madeleine Rüthrich, et al. · Annals of Hematology · 168
PDF
Urinary Frequency as a Possibly Overlooked Symptom in COVID-19 Patients: Does SARS-CoV-2 Cause Viral Cystitis?
2020 · Jan-Niclas Mumm, Andreas Osterman, et al. · European Urology · 142
Dynamics of SARS-CoV-2 shedding in the respiratory tract depends on the severity of disease in COVID-19 patients
2021 · Dieter Munker, Andreas Osterman, et al. · European Respiratory Journal · 64
PDF
Sequential Versus Combination Therapy of Metastatic Colorectal Cancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study—XELAVIRI (AIO KRK0110)
2018 · Dominik Paul Modest, Ludwig Fischer von Weikersthal, et al. · Journal of Clinical Oncology · 50
Preoperative serum markers for individual patient prognosis in stage I–III colon cancer
2015 · Clemens Giessen-Jung, Dorothea Nagel, et al. · Tumor Biology · 46
Economic evaluation of genetic screening for Lynch syndrome in Germany
2015 · Franziska Severin, Björn Stollenwerk, et al. · Genetics in Medicine · 44
The cost-effectiveness of UGT1A1 genotyping before colorectal cancer treatment with irinotecan from the perspective of the German statutory health insurance
2015 · Bettina Butzke, Fuat S. Oduncu, et al. · Acta Oncologica · 41
PDF
ChatGPT's Gastrointestinal Tumor Board Tango: A limping dance partner?
2024 · Ughur Aghamaliyev, Javad Karimbayli, et al. · European Journal of Cancer · 34
PDF
Amphiregulin Expression Is a Predictive Biomarker for EGFR Inhibition in Metastatic Colorectal Cancer: Combined Analysis of Three Randomized Trials
2020 · Arndt Stahler, Sebastian Stintzing, et al. · Clinical Cancer Research · 26
Prevalence and influence on outcome of HER2/neu, HER3 and NRG1 expression in patients with metastatic colorectal cancer
2017 · Arndt Stahler, Volker Heinemann, et al. · Anti-Cancer Drugs · 22
Current treatment options in RAS mutant metastatic colorectal cancer patients: a meta-analysis of 14 randomized phase III trials
2020 · Arndt Stahler, Volker Heinemann, et al. · Journal of Cancer Research and Clinical Oncology · 21
PDF
Multidisciplinary treatment of colorectal liver metastases
2017 · Tobias S. Schiergens, Jobst von Einem, et al. · Minerva Medica · 18
Efficacy of FOLFIRI plus cetuximab vs FOLFIRI plus bevacizumab in 1st-line treatment of older patients with RAS wild-type metastatic colorectal cancer: an analysis of the randomised trial FIRE-3
2022 · Laura E. Fischer, Sebastian Stintzing, et al. · British Journal of Cancer · 17
PDF
Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110)
2021 · Kathrin Heinrich, Dominik P. Modest, et al. · European Journal of Cancer · 16
PDF
Baseline Health-related Quality of Life Predicts Bladder Cancer–specific Survival Following Radical Cystectomy
2022 · Thilo Westhofen, Lennert Eismann, et al. · European Urology Focus · 13
KRAS exon 2 mutations influence activity of regorafenib in an SW48-based disease model of colorectal cancer
2015 · Peter Camaj, Stefano Primo, et al. · Future Oncology · 13
Chemotherapie-induzierte periphere Neuropathie
2018 · Clemens Gießen-Jung, Louisa von Baumgarten · DMW - Deutsche Medizinische Wochenschrift · 12
Analysis of Circulating Immune Subsets in Primary Colorectal Cancer
2022 · Can Lu, Josefine Schardey, et al. · Cancers · 11
PDF
Impact of primary tumor sidedness and sex on prognosis and anti-epidermal growth factor receptor antibody efficacy in BRAF-mutant metastatic colorectal cancer: a pooled analysis of AIO studies FIRE-1, CIOX, FIRE-3, XELAVIRI, and VOLFI
2024 · A.H.S. Alig, D.P. Modest, et al. · ESMO Open · 10
PDF
Dynamics of urinary and respiratory shedding of Severe acute respiratory syndrome virus 2 (SARS-CoV-2) RNA excludes urine as a relevant source of viral transmission
2021 · Jan-Niclas Mumm, Stephan Ledderose, et al. · Infection · 8
PDF
Consensus molecular subtypes in metastatic colorectal cancer treated with sequential versus combined fluoropyrimidine, bevacizumab and irinotecan (XELAVIRI trial)
2021 · Arndt Stahler, Volker Heinemann, et al. · European Journal of Cancer · 8
Miliary pattern of brain metastases – a case report of a hyperacute onset in a patient with malignant melanoma documented by magnetic resonance imaging
2015 · Florian P. Reiter, Clemens Giessen-Jung, et al. · Radiation Oncology · 8
PDF
Works count: 72
Citation count: 1,817
H-index: 16
I10-index: 22
Year
Topic
Type